Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 14, 2026OncologyOpen Access

FLAG-Based Versus Standard 7+3 Induction Therapy in Adults with Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMohammed AbdulgayoomSASoha AboukhalafMOMahmoud Osman

Discussion

Loading...

Member takes

Overview

Systematic review compares response rates and mortality in adults with acute myeloid leukemia, suggesting FLAG-based may be effective.

Key Points

  • This research aims to compare FLAG-based induction therapy with the standard 7+3 regimen for adults with newly diagnosed acute myeloid leukemia.
  • Conducted a systematic review and meta-analysis following PRISMA 2020 guidelines.
  • Analyzed data from five retrospective cohort studies involving 534 patients.
  • Compared overall response rates, mortality rates at 30 and 60 days, and assessed consolidation therapy rates.
  • FLAG-based induction showed a higher overall response rate than 7+3 (OR 1.83, 95% CI 1.03–3.22).
  • No significant difference in 30-day mortality (OR 0.56, 95% CI 0.12–2.69) or 60-day mortality (OR 0.79, 95% CI 0.29–2.14).
  • Survival outcomes varied across studies with inconsistent reporting of disease-free survival (DFS) and overall survival (OS) metrics.

Cite This Study

Abdulgayoom et al. (2026) studied this question.

synapsesocial.com/papers/6a2e4779b1cc60ccdea8beebhttps://doi.org/10.1159/000552987
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative outcomes of FLAG-based versus standard 3+7 induction therapy in adults with newly diagnosed acute myeloid leukemia: A systematic review and meta-analysis.2026
  2. 2FLAG-IDA as frontline induction improves outcomes in pediatric patients with core-binding factor or KMT2A-rearranged acute myeloid leukemia: A multicenter cohort study in southern China2025 · 1 citations
  3. 3FLAG/FLAG-Ida Regimen in Secondary and Relapsed/Refractory Acute Myeloid Leukemia—Even in the Era of New Treatment Modalities Still a Significant Player2024 · 5 citations
  4. 4Ratifying the efficacy and safety of intensive induction chemotherapy for acute myeloid leukaemia by the Australasian Leukaemia & Lymphoma Group consensus approach2025 · 3 citations
  5. 5Therapy related core binding factor Acute Myeloid Leukemia (CBF-AML) responds favorably to fludarabine, cytarabine, GCSF (FLAG) based therapy: Exploratory Analysis from a Phase 2 trial2025